Previous close | 12.50 |
Open | 12.50 |
Bid | 11.10 |
Ask | 14.90 |
Strike | 15.00 |
Expiry date | 2024-12-20 |
Day's range | 12.50 - 12.50 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price might be vulnerable to...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buye
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in the U.S.; potential to generate royalties exceeding $150 million annually Royalty Pharma to host investor call today,